Home > Insider Trading > Filing (0001213900-20-016762)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1811063	Panacea Acquisition Corp	PANA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1454385	Oleg Nodelman	C/O Panacea Acquisition Corp., 357 Tehama Street, Floor 3 San Francisco CA 94103	Ceo And Chairman Of The Board	Yes	Yes	No	No
1567938	Ecor1 Capital Fund, L.p.	C/O Panacea Acquisition Corp., 357 Tehama Street, Floor 3 San Francisco CA 94103		Yes	No	Yes	No
1587114	Ecor1 Capital, Llc	C/O Panacea Acquisition Corp., 357 Tehama Street, Floor 3 San Francisco CA 94103		Yes	No	Yes	No
1598292	Ecor1 Capital Fund Qualified, L.p.	C/O Panacea Acquisition Corp., 357 Tehama Street, Floor 3 San Francisco CA 94103		Yes	No	Yes	No
1778011	Ecor1 Venture Opportunity Fund, Lp	C/O Panacea Acquisition Corp., 357 Tehama Street, Floor 3 San Francisco CA 94103		Yes	No	Yes	No
1816134	Ecor1 Panacea Holdings, Llc	C/O Panacea Acquisition Corp., 357 Tehama Street, Floor 3 San Francisco CA 94103		Yes	No	Yes	No
1816370	Biotech Opportunity Gp, Llc	C/O Panacea Acquisition Corp., 357 Tehama Street, Floor 3 San Francisco CA 94103		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2020-07-06	390,000	$10.00	390,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

The reported shares are included within the 390,000 private placement units of the issuer purchased by EcoR1 Panacea Holdings, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of Class A common stock of the issuer and one-third of one redeemable warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering.
The reporting owner, the Sponsor, in whose name the securities reported herein are held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.